Lead Product(s) : Nepicastat
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Asieris Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
Details : SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $0.5 million
August 29, 2022
Lead Product(s) : Nepicastat
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Asieris Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
